TheranosticTrials.org

Clinical Trial · NCT07621146

A Comparison of [68Ga]DOTATATE and [18F]AmBF3TATE for the Staging and Assessment of Neuroendocrine Malignancies

Overview

Neuroendocrine tumours (NETs) are generally slow growing, but some can be aggressive and resistant to treatment. Compared to healthy cells, the surface of these tumor cells has a greater number of molecules called somatostatin receptors (SSTR) which requires specific PET scan tracers to sufficiently capture on images. The current standard of care tracer at BC Cancer for SSTRs on NETs is 68Ga-DOTATATE. This project seeks to identify if 18F-AmBF3-TATE (a tracer that has established safety from phase 1 trial results), is comparable in disease detection, no. of lesions identified, image quality, safety and overall accuracy, to 68Ga-DOTATATE.

Sponsor

British Columbia Cancer Agency

Contacts

Administrative Research Manager (CONTACT)

mitclinicaltrials@bccancer.bc.ca

604-877-6000

Research Project Manager (CONTACT)

mitclinicaltrials@bccancer.bc.ca

604-675-8000

Ian Alberts, MBBS MD PhD FEBNM (PRINCIPAL_INVESTIGATOR)

ClinicalTrials.gov

NCT07621146

Drug / Compound

AmBF3-TATE

Isotope(s):
Target(s):
  • SSTR2
Ligand Class: Peptides

DOTATATE

Isotope(s):
Target(s):
  • SSTR2
Ligand Class: Peptides
Chelator: DOTA

Eligibility

Inclusion

  • Patients referred for and meeting institutional criteria for a \[68Ga\]DOTATATE PET/CT for the investigation of a known or suspected neuroendocrine malignancy (BC Cancer criteria APPENDIX A).
  • * Age ≥18 years

Exclusion

  • Patients exceeding the safe weight limit of the scanner (204.5 kg) or who cannot fit through the PET/CT bore (70cm diameter).
  • * Pregnant and breast-feeding patients.
  • Patients unwilling or unable to undergo a second PET/CT.